We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

80 hedge funds and large institutions have $79.4M invested in Arbutus Biopharma in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 12

83% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 12

23% more funds holding

Funds holding: 65 → 80 (+15)

5% more capital invested

Capital invested by funds: $75.5M → $79.4M (+$3.9M)

2.87% less ownership

Funds ownership: 29.12% → 26.25% (-2.9%)

32% less call options, than puts

Call options by funds: $4.67M | Put options by funds: $6.87M

Holders
80
Holders Change
+15
Holders Change %
+23.08%
% of All Funds
1.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
22
Reduced
12
Closed
12
Calls
$4.67M
Puts
$6.87M
Net Calls
-$2.2M
Net Calls Change
-$1.83M

Top Buyers

1
BlackRock
BlackRock
New York
+$2.72M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.77M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.53M
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$1.2M
5
Group One Trading
Group One Trading
Illinois
+$893K

Top Sellers

1
FCMI
Foresite Capital Management IV
California
-$10.4M
2
Morgan Stanley
Morgan Stanley
New York
-$5.21M
3
Goldman Sachs
Goldman Sachs
New York
-$682K
4
Deutsche Bank
Deutsche Bank
Germany
-$400K
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$139K
Name Holding Trade Value Shares
Change 		Change in
Stake
Daiwa Securities Group
76
Daiwa Securities Group
Japan
$1K +$560 +160 New
Barclays
77
Barclays
United Kingdom
$1K +$1.37K +391 New
FCMI
78
Foresite Capital Management IV
California
– -$10.4M -3,332,616 Closed
Deutsche Bank
79
Deutsche Bank
Germany
– -$400K -127,785 Closed
Assenagon Asset Management
80
Assenagon Asset Management
Luxembourg
– -$139K -44,362 Closed
BIM
81
Bogle Investment Management
Massachusetts
– -$131K -41,700 Closed
Mackenzie Financial
82
Mackenzie Financial
Ontario, Canada
– -$125K -39,900 Closed
EGM
83
Engineers Gate Manager
New York
– -$93K -29,600 Closed
CL
84
CSS LLC
Illinois
– -$93.5K -26,700 Closed
Two Sigma Advisers
85
Two Sigma Advisers
New York
– -$75K -24,100 Closed
BCM
86
Bayesian Capital Management
New York
– -$64K -20,600 Closed
VFA
87
Valeo Financial Advisors
Indiana
– -$25K -8,000 Closed
SM
88
SG3 Management
Puerto Rico
– -$19.1K -5,464 Closed
JP Morgan Chase
89
JP Morgan Chase
New York
– +$126 +36 New
1 2 3
4

ABUS Hedge Fund Activity: Q4 2020 in Review

80 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2020, worth a combined $79.4M — up 5.2% from $75.5M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new ABUS positions and 12 closed out — a net gain of 16 holders — while 22 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $2.72M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $10.4M sold.

  • 80 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2020, up from 65 in Q3 2020.
  • Funds reported $79.4M of Arbutus Biopharma stock for Q4 2020, up 5.2% quarter-over-quarter.
  • 28 funds opened new Arbutus Biopharma positions in Q4 2020 and 12 closed out, a net change of +16 holders.
  • The largest Arbutus Biopharma buyer in Q4 2020 was BlackRock, an estimated $2.72M added.
  • The largest Arbutus Biopharma seller in Q4 2020 was Foresite Capital Management IV, an estimated $10.4M sold.

Based on aggregated 13F filings for Q4 2020.